Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 2 – Translational research

4924 - Analysis of the Androgen Receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients


30 Sep 2019


Poster Discussion 2 – Translational research


Marzia Del Re


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


M. Del Re1, V. Conteduca2, S. Crucitta3, G. Gurioli2, C. Casadei2, G. Restante4, G. Schepisi5, C. Lolli6, R. Morganti7, R. Danesi8, U.F.F. De Giorgi9

Author affiliations

  • 1 Laboratory Medicine, Azienda Ospedaliero Universitaria Pisana, 56126 - Pisa/IT
  • 2 Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 3 Clinical And Experimental Medicine, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 4 Clinical Pharmacology And Pharmacogenetics, University of Pisa, 56126 - Pisa/IT
  • 5 Oncology Dept., Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 6 Oncology Unit, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 7 Clinical And Experimental Medicine, university Hospital of Pisa, 56010 - Pisa/IT
  • 8 Clinical And Experimental Medicine, University of Pisa, 56126 - Pisa/IT
  • 9 Medical Oncology Department, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4924


Abiraterone and enzalutamide represent the standard treatment in castration resistance prostate cancer (CRPC) patients, however, some patient displays primary resistance, and several studies investigated the role of the androgen receptor (AR) as a predictive biomarker of response to treatment (Conteduca, et al. Ann Oncol. 2017;28(7):1508-1516; Del Re, et al. BJU Int. 2019 doi: 10.1111/bju.14792). The present study is aimed at evaluating the role the AR in liquid biopsy to predict response to hormone treatment in CRPC patients.


Six ml of plasma samples were collected from patients affected by castration-resistant prostate cancer before the beginning of first-line hormonal treatment. Circulating free DNA and exosome-RNA were isolated for analysis of AR-gain and AR-V7 by digital droplet PCR.


Eighty-four CRPC were prospectively enrolled in this study. 40 patients received abiraterone and 44 patients received enzalutamide as first-line hormonal therapy. AR-gain was detected in 12 patients (14.3%) and 36% were AR-V7+ at baseline. Median PFS and OS were significantly longer in AR-V7- vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p < 0.0001, respectively). Patients carrying of the AR-gain had a median PFS of 4.8 vs 24.3 months of non-gained AR patients (P < 0.0001). Median OS was significantly longer in AR-no gain vs AR-gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR-gain was observed (r = 0.28; p = 0.01). In the univariate model, known risk factors for progression such as AR-V7, AR-gain, neutrophil/lymphocyte ratio and metastatic spread to either bone or lymph nodes were analysed. In multivariable analysis, only AR-V7 and AR gain were confirmed as independent predictive biomarkers (p < 0.0001 and p = 0.004, respectively).


The present study demonstrates that cfDNA and exosomal RNA are a reliable source of AR-variants and their detection predicts resistance to anti-hormonal therapy. The method is sensitive, fast and represents a convenient alternative to other potentially more expensive and less sensitive approaches.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


V. Conteduca: Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Astellas; Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Bayer. U.F.F. De Giorgi: Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Sanofi; Advisory/Consultancy: Astellas; Advisory/Consultancy: Byer; Advisory/Consultancy: BMS; Honoraria (self): Ipsen; Advisory/Consultancy: Janssen; Advisory/Consultancy: Merk; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Sanofi; Travel/Accommodation/Expenses: BMS; Travel/Accommodation/Expenses: Ipsen; Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.